Dicyclomine Hydrochloride + Chlordiazepoxide + Clidinium BromideThird Party Manufacturing in India

This triple-action formulation combines two antispasmodic agents with an anxiolytic to address both the physical and emotional components of functional gastrointestinal disorders.

Dicyclomine hydrochloride relieves smooth muscle spasm of the gastrointestinal tract through a dual mechanism. It acts as a specific anticholinergic agent by competitively blocking muscarinic acetylcholine receptors, approximately one-eighth as potent as atropine on a milligram basis. Additionally, dicyclomine exerts a direct musculotropic effect on smooth muscle by antagonizing bradykinin- and histamine-induced spasms. This dual action makes it effective in reducing GI spasm without the systemic anticholinergic burden of more potent agents.

Clidinium bromide is a synthetic quaternary ammonium anticholinergic compound that inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites, primarily by blocking M1 and M3 muscarinic receptors. It produces pronounced antispasmodic and antisecretory effects on the gastrointestinal tract, reducing hypermotility, gastric acid secretion, and cramping pain.

Chlordiazepoxide, a benzodiazepine, binds to stereospecific benzodiazepine binding sites on GABA-A receptor complexes in the central nervous system. This enhances the effect of the inhibitory neurotransmitter GABA by increasing the frequency of chloride ion channel opening, resulting in anxiolytic, sedative, and muscle relaxant effects. It addresses the emotional stress and anxiety that often accompany or exacerbate functional GI disorders.

The combination provides comprehensive management of irritable bowel syndrome by targeting smooth muscle spasm, hypersecretion, and anxiety-driven gut dysfunction simultaneously.

Therapeutic Uses

Dicyclomine Hydrochloride + Chlordiazepoxide + Clidinium Bromide is indicated for the treatment of:

• Irritable Bowel Syndrome: Particularly IBS with diarrhea-predominant symptoms where abdominal cramping, urgency, and emotional stress are significant components. The combination addresses both the hypermotility and the anxiety that often triggers or worsens IBS episodes.
• Peptic Ulcer Disease: As adjunctive therapy to reduce gastric acid secretion, relieve associated smooth muscle spasm, and manage the anxiety component of chronic ulcer disease.
• Spastic Colon: For patients with colonic hypermotility presenting with cramping abdominal pain, alternating bowel habits, and bloating.
• Acute Enterocolitis: For symptomatic relief of abdominal cramps and hypermotility during acute gastrointestinal infections where smooth muscle relaxants are indicated.
• Functional Dyspepsia: For patients with upper abdominal discomfort where both motility disturbance and emotional factors play a role in symptom generation.

Why Manufacturers Choose This Combination

The Dicyclomine + Chlordiazepoxide + Clidinium combination is a well-established GI product in the Indian pharmaceutical market, marketed under various brand names as branded generic equivalents. It offers PCD franchise partners a specialized GI product with consistent prescription demand from gastroenterologists and general practitioners. Indian WHO-GMP certified manufacturers produce this combination for both domestic distribution and export to regulated markets in Africa, Asia, and the Middle East. The manufacturing process for combination tablets is well-established in facilities across Himachal Pradesh and Gujarat. Strong demand from the growing IBS patient population and the lack of direct OTC substitutes make this a reliable product line for third-party manufacturing partnerships.